Assessment of high-dose acetylcysteine in acute high-risk paracetamol (acetaminophen) ingestion

• Published in: Clinical toxicology (Philadelphia, Pa.) Pa.), 2024-08, Vol.62 (8), p.519-525
• Main Authors: Moss, Michael J, Hinchman, Brynne, Lambson, Joseph E, Scott, Julie W, Hinckley, Paul, Wylie, Sawyer J, Dorey, Alyrene
• Format: Article
• Language: English
• Subjects: Acetaminophen - administration & dosage; Acetaminophen - poisoning; Acetylcysteine - administration & dosage; Acetylcysteine - therapeutic use; Adolescent; Adult; Analgesics, Non-Narcotic - administration & dosage; Analgesics, Non-Narcotic - poisoning; Antidotes - administration & dosage; Antidotes - therapeutic use; Chemical and Drug Induced Liver Injury - etiology; Chemical and Drug Induced Liver Injury - prevention & control; Dose-Response Relationship, Drug; Drug Overdose - drug therapy; Female; Humans; Male; Middle Aged; Poison Control Centers - statistics & numerical data; Retrospective Studies; Young Adult
• ISSN: 1556-3650; 1556-9519; 1556-9519
• DOI: 10.1080/15563650.2024.2377268

Prompt acetylcysteine treatment with standard doses (300 mg/kg over 21 h in divided doses) is almost universally effective in preventing hepatotoxicity after paracetamol (acetaminophen) overdose. However, hepatotoxicity is reported despite early treatment when paracetamol concentrations exceed 300 mg/L (1,985 μmol/L) at 4 h. Prior studies evaluating high-dose acetylcysteine to treat high-risk ingestions have shown mixed results. We compared outcomes in patients with high-risk ingestions receiving standard or high-dose acetylcysteine. Records from a single poison center were reviewed from 1 January 2017 to 31 December 2022. We included cases of acute paracetamol ingestion treated with intravenous acetylcysteine with an initial paracetamol concentration above the "300 mg/L" (1,985 μmol/L) line on the Rumack-Matthew nomogram. We compared standard and high-dose acetylcysteine groups by odds ratios and multivariable logistic regression. We defined hepatotoxicity as aminotransferase activity >1,000 U/L. We included 190 cases. Fifty-six percent received standard-dose acetylcysteine while 44% received high-dose acetylcysteine. Treatment within 8 h yielded no difference in hepatotoxicity between groups (odds ratio 1.67, 95% CI 0.067-42.3). Among patients treated after 8 h, hepatoxicity was more common in the high-dose group (odds ratio 3.39, 95% CI 1.25-9.2) though odds of liver failure were similar (odds ratio 2.78, 95% CI 0.89-8.69). Eighty-eight percent of patients with hepatotoxicity had elevated aminotransferase activity at presentation. No patient died or received a liver transplant. Rates of hepatotoxicity were low in patients treated within 8 h regardless of acetylcysteine dose. Unexpectedly, high-dose acetylcysteine treatment was associated with an increased odds of hepatoxicity in those treated after 8 h, but most had abnormal aminotransferase activities at presentation and there was no difference in rates of liver failure. Limitations include the use of retrospective, voluntarily reported poison center data. Prompt treatment with acetylcysteine, regardless of dose, prevented hepatotoxicity in high-risk paracetamol ingestion.